This study provides novel insights into the expression and clinical significance of CXCR5 and LAG‐3 in peripheral blood CD8+ T cells of DLBCL patients, demonstrating that expression of these markers correlates with decreased 5‐year OS post‐treatment. Here, LAG3 is linked to diffuse large B-cell lymphoma.